On September 2, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that the Company will participate in Wells Fargo’s Virtual Healthcare Conference and H.C. Wainwright’s 23rd Annual Global Investment Conference being held virtually (Press release, Infinity Pharmaceuticals, SEP 2, 2021, View Source [SID1234587159]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details can be found below:

Wells Fargo Virtual Healthcare Conference
Format: Fireside chat and 1-on-1 meetings
Date and Time: Fireside chat September 9 th at 2:40pm ET; 1-on-1 meetings September 9-10
Webcast Link: View Source
H.C. Wainwright Virtual 23rd Annual Global Investment Conference
Format: On demand presentation and 1-on-1 meetings
Date and Time: Presentation available Monday, September 13 th 7am ET; 1-on-1 meetings September 13-15
Registration Link
The presentations and archived webcasts can be accessed in the Investors/Media section of Infinity’s website at www.infi.com and will be available on Infinity’s website for 30 days following the event.